戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nd/or the gastrointestinal tract (persistent vomiting).
2 ing, eye bulging, bradycardia, cyanosis, and vomiting.
3 ad nausea and 15 (17%) versus three (5%) had vomiting.
4 spitalization, and frequency of diarrhea and vomiting.
5  complaints of epigastric abdominal pain and vomiting.
6 , headache, nausea, diarrhea, dizziness, and vomiting.
7 culitis accompanying with abdominal pain and vomiting.
8  of vision in her right eye, ocular pain and vomiting.
9 , but increases the occurrence of nausea and vomiting.
10 ED visits for gastroenteritis, diarrhea, and vomiting.
11 o an adverse event, oxygen desaturation, and vomiting.
12 e than glargine, were nausea, diarrhoea, and vomiting.
13 per abdominal pain radiating to the back and vomiting.
14 verse events (AEs) were fatigue, nausea, and vomiting.
15 ctory and somatosensory stimuli, nausea, and vomiting.
16  a 2-day history of abdominal distention and vomiting.
17 esented with a history of abdominal pain and vomiting.
18  low risk of chemotherapy-induced nausea and vomiting.
19 ss of consciousness, headache, and/or nausea/vomiting.
20 adverse events such as nausea, diarrhea, and vomiting.
21 eduction in PTH) and self-reported nausea or vomiting.
22 s and specific symptoms of pain, nausea, and vomiting.
23 acial dysmorphisms, and periods of fever and vomiting.
24  by risk for chemotherapy-induced nausea and vomiting.
25 nted acutely with severe epigastric pain and vomiting.
26 om Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1
27 and promethazine after 24 hours (episodes of vomiting, 1 [IQR, 0-5] for metoclopramide vs 2 [IQR, 0-3
28 ausea (12.4% and 9.1% vs 5.1% and 7.3%), and vomiting (10.4% and 7.5% vs 7.1% and 3.1%).
29  [3.7%] vs. 74 patients [6.2%]; P=0.006) and vomiting (100 patients [8.4%] vs. 194 patients [16.2%];
30 e nausea (16%), prolonged QT interval (12%), vomiting (11%), and dysgeusia (11%); most were </= grade
31 tigue (18 [56%] of 32 vs two [40%] of five), vomiting (12 [38%] of 32 vs zero), and anaemia (eight [2
32  [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotr
33 s included nausea (eight [7%] vs one [<1%]), vomiting (13 [11%] vs one [<1%]), musculoskeletal pain (
34 eutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).
35 6 [15%] of 233 patients vs five [2%] of 223; vomiting: 15 [6%] vs six [3%]; diarrhoea: 32 [14%] vs 15
36 rthralgia (4 [5%] vs 1 [1%]), and nausea and vomiting (2 [2%] vs 3 [4%]).
37 nia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2
38  [54% vs 23%; P < .001] and grade 3/4 nausea/vomiting [20% vs 11%; P = .03]), while rates of grade 3
39  [12%]), dyspepsia (24 [8%] vs 18 [6%]), and vomiting (21 [7%] vs 25 [8%]), with similar rates of stu
40 nts in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3.9%; P = .0
41 inal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]).
42 were neutropenia (30 [27%] of 113 patients), vomiting (22 [19%]), and leucopenia (17 [15%]).
43 th neutropenia (30 [26.5%] of 113 patients), vomiting (22 [19.5%]), and leucopenia (17 [15.0%]) in th
44 erythrodysaesthesia syndrome (87 [18%]), and vomiting (24 [5%]).
45  CF versus LRD results were as follows: POD2 vomiting (28% vs 14%; P = 0.09), and significant increas
46 vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [18%]), and diarrhoea (22 [34%]
47  upper gastrointestinal hemorrhage (3%), and vomiting (3%).
48 Rash (84 reports), itching (46 reports), and vomiting (30 reports) were the 3 most frequently occurri
49 xygen desaturation (353 patients [5.6%]) and vomiting (328 [5.2%]) were the most common of these adve
50 joint pains, 37 (5%) had nausea, 36 (4%) had vomiting, 34 (4%) had neuropathy, 23 (3%) had transamini
51 rhea (38%), nausea (38%), fatigue (37%), and vomiting (35%).
52 el-prednisone, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased
53 hea [86%/83%/74%], nausea [46%/48%/48%], and vomiting [37%/38%/43%]).
54  [5%] vs 23 [corrected] [3%]), and nausea or vomiting (38 [5%] vs 41 [6%]).
55 ea (56 [10%] of 556 vs 64 [11%] of 585), and vomiting (39 [7%] of 556 vs 23 [4%] of 585).
56 nausea (75%), fatigue (70%), anorexia (64%), vomiting (43%), weight loss (32%), and diarrhea (32%), w
57 group), diarrhoea (59 [13%] vs 28 [6%]), and vomiting 48 [11%] vs 17 [4%]), which occurred less frequ
58  thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events.
59 gue (70%), nausea (70%), anorexia (66%), and vomiting (49%), which were generally grade 1 or 2.
60 luded fever (91%), abdominal pain (84%), and vomiting (49%).
61 6% [49 of 57]), ataxia (54% [29 of 54]), and vomiting (54% [29 of 54]) were common initial clinical m
62 up and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the chemo
63  not affect time to resolution of nausea and vomiting (64.5 vs 74.3 hours; P = 0.404) or consumption
64 and 8 [31%] patients in DRMPa200Z group) and vomiting (7 [12%] patients in MPa100Z group, 7 [11%] pat
65 7.0%), headache (77.9%), joint pain (73.7%), vomiting (71.2%), and diarrhea (70.6%).
66 30.7% [95% CI, 26.8%-34.7%]; P = .01) and no vomiting (87.1% [95% CI, 83.8%-90.0%) vs 78.0% [95% CI,
67 1.6% [95% CI, 37.4%-45.3%]; P < .001) and no vomiting (91.8% [95% CI, 89.0%-94.0%] vs 82.2% [95% CI,
68  sick with typical NoV infection symptoms of vomiting (93.4%), abdominal pain (90.4%), nausea (60.0%)
69  glucose levels in motion-induced nausea and vomiting, a finding that may provide insight into other
70  associated with reduced odds of posttussive vomiting, a marker of more clinically significant illnes
71 ose, he presented with headache, nausea, and vomiting; a brain magnetic resonance imaging scan showed
72 ts or who experience breakthrough nausea and vomiting; a recommendation to administer dexamethasone o
73               Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were assessed b
74 ge to the ENS or developmental defects cause vomiting, abdominal pain, constipation, growth failure,
75 number of symptoms and higher frequencies of vomiting, abdominal pain, swollen stomach, and loss of a
76             For radiation-induced nausea and vomiting, adjustments were made to anatomic regions, ris
77                       Importance: Nausea and vomiting affects approximately 85% of pregnant women.
78         In each treatment group, the risk of vomiting after administration of any dose of the study a
79 tient began to experience abdominal pain and vomiting after ingestion of egg approximately one day af
80  children treated with ondansetron continued vomiting after the administration of the therapy vs 93%
81 ol group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ administration).
82 findings (>60 years, intoxication, headache, vomiting, amnesia, seizure, or trauma above the clavicle
83                                       Recent vomiting and abdominal discomfort were due to a high-gra
84 tolerated; the most common side effects were vomiting and abdominal pain.
85 prokinetic effects and significantly reduced vomiting and also improved other symptoms of diabetic ga
86                                              Vomiting and bloody stool were frequently observed in bo
87                                              Vomiting and cough were prevalent symptoms in the first
88 t requiring surgery [grade 3]; recurrence of vomiting and dehydration [grade 3]; diarrhoea and fever
89 s each year as a result of severe diarrhoea, vomiting and dehydration due to the actions of cholera t
90 s and other animals that is characterized by vomiting and diarrhea and caused by a variety of pathoge
91                  The final patient developed vomiting and diarrhea, started palliative care, and died
92 ted in Ireland caused illness manifesting by vomiting and diarrhoea.
93                                Incidences of vomiting and drug-hypersensitivity reactions were signif
94 ea and G4 thrombocytopenia at 350 mg; and G3 vomiting and G3 diarrhea at 500 mg.
95 mptomatic in 2 patients and symptomatic with vomiting and headache in 2 patients.
96                                       He was vomiting and in distress, and he had a history of thalas
97 izophrenia-like behaviours, anxiety, memory, vomiting and pain.
98 with evidence of dehydration associated with vomiting and severe diarrhea.
99 s); adverse events were primarily nausea and vomiting and sleep disorders.
100 s ribavirin due to serious adverse events of vomiting and tachycardia.
101 ECS is involved in the control of nausea and vomiting and visceral sensation.
102  53-year-old woman presented with nausea and vomiting and was noted to have an asymptomatic elevated
103 ; P = .068), and mild or greater severity of vomiting and/or diarrhea (20.0% vs. 37.5%; P = .074) wer
104 ovirus VLP vaccine reduced norovirus-related vomiting and/or diarrhea; field efficacy studies are pla
105  with acute gastroenteritis (diarrhea and/or vomiting) and 818 healthy controls frequency matched by
106 us, pain, presyncope, urinary retention, and vomiting) and one patient had a grade 4 adverse event (l
107 nal-reported morbidity (fever, diarrhea, and vomiting) and serious infectious events (SIEs) (gastroen
108  (15%) dysgeusia, 18 (28%) versus five (15%) vomiting, and 12 (19%) versus two (6%) neutropenia.
109 ase characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea.
110  presents itself in association with nausea, vomiting, and abnormal sensitivity to light, noise, and
111 eumonia, ileus, and postoperative nausea and vomiting, and also improved recovery of bowel function,
112 reaction including erythema, abdominal pain, vomiting, and anaphylactic shock.
113  than men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to vary by ge
114  despite severe side effects such as nausea, vomiting, and anorexia that compromise quality of life a
115                                      Nausea, vomiting, and asymptomatic hyperCKemia should be recogni
116 o group were arthralgia, diarrhea, pruritus, vomiting, and chest pain.
117 old man had acute onset of headache, nausea, vomiting, and confusion.
118 ose-limiting toxicities were grade 3 nausea, vomiting, and diarrhea in 2 patients, and grade 3 skin r
119                                      Nausea, vomiting, and diarrhea were more common in the apremilas
120 equent adverse events were low-grade nausea, vomiting, and diarrhea.
121 nificantly associated with death were fever, vomiting, and diarrhoea.
122 e world during childhood and cause diarrhea, vomiting, and fever.
123 e world during childhood and cause diarrhea, vomiting, and fever.
124 0(th) %ile of normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily
125 r (D2R) antagonist approved to treat nausea, vomiting, and headache in humans has potent in vitro and
126 e the early signs of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3% sodium
127 enia (n=4), diarrhoea (n=2), melena, stroke, vomiting, and intestinal infarction; all but one patient
128 ropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in pati
129 common (31 participants with nausea, 31 with vomiting, and one with diarrhoea), then oral pruritus af
130 that early solid intake may increase nausea, vomiting, and overall complications.
131 ique on postoperative opioid use, nausea and vomiting, and pain scores.
132 stroesophageal reflux disease [GERD], nausea/vomiting, and pain) align with clinical symptomology and
133 iated with savolitinib were nausea, fatigue, vomiting, and peripheral edema.
134 physiological changes resulting in diarrhea, vomiting, and proinflammatory diseases, making both the
135  oral rehydration salt solution, severity of vomiting, and serum levels of rotavirus-specific IgA.
136 female, professional diver, reported nausea, vomiting, and systemic hives 20 to 30 minutes after inge
137 mon clinical features include fever, nausea, vomiting, and tinnitus.
138 al with acute abdominal pain, diarrhoea, and vomiting, and was admitted to the hospital because of de
139  epigastric pain, postprandial pain, nausea, vomiting, and weight loss.
140 participants, included nausea, diarrhea, and vomiting, and were mild in severity.
141 d adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed
142 hat devastate quality of life (e.g., nausea, vomiting, anorexia, weight loss).
143  In Rome IV functional nausea and functional vomiting are now described.
144 educed the half-time of gastric emptying and vomiting, as well as nausea, abdominal pain, bloating, a
145 oup had CPAP-related adverse events, such as vomiting, aspiration, and nasal, skin, or eye trauma.
146 inol and nabilone), which include nausea and vomiting associated with chemotherapy and appetite stimu
147 is (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in cancer patients
148 etic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic
149 ot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%).
150 ed trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s
151 symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s
152 n to prevent chemotherapy-induced nausea and vomiting (CINV) for patients undergoing high-dose chemot
153  the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely considered whe
154 , ranging from 0.10 for anorexia to 0.54 for vomiting (Cohen kappa statistic).
155 d gastric emptying and significantly reduced vomiting, compared with placebo.
156 definitions of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, f
157 sicians of six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and hair loss) within
158               Chronic unexplained nausea and vomiting (CUNV) is a debilitating disease of unknown cau
159 severe hypercalcemia with failure to thrive, vomiting, dehydration, and nephrocalcinosis.
160 ially preventable conditions such as nausea, vomiting, dehydration, and pain.
161 noses were infectious causes (46.3%), nausea/vomiting/dehydration (26.8%), and pain (6.1%).
162 who presented with acute epigastric pain and vomiting, diagnosed to have an incarcerated diaphragmati
163 eloped abruptly with fevers, abdominal pain, vomiting, diarrhea, dehydration, and hemorrhage.
164 minor adverse events were reported including vomiting, diarrhoea, cystitis, gastroenteritis, and blee
165  IGBs from the patient's body causes nausea, vomiting, discomfort, and even gastric mucous damage.
166 outh, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of
167 e associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infecti
168 revention of chemotherapy-induced nausea and vomiting during the 5-day (0-120 h) at-risk period after
169 revention of chemotherapy-induced nausea and vomiting during the at-risk period (120 h) after adminis
170 topenia, gastrointestinal events (diarrhoea, vomiting, dysgeusia, mucositis), fatigue, and hyponatrae
171  patients (52%) and preceded by a nausea and vomiting episode in 2 patients (8%).
172 5% CI, 2.8-8.5; specificity, 97%), 2 or more vomiting episodes (LR, 3.6; 95% CI, 3.1-4.1; specificity
173 rrent or prior optic neuritis or intractable vomiting episodes more frequently, had shorter time to m
174 =2 vomiting episodes without diarrhea or 1-2 vomiting episodes plus 1-2 loose/liquid stools within 24
175 anded case definition of AGE (by adding >/=2 vomiting episodes without diarrhea or 1-2 vomiting episo
176 the Canadian CT Head Rule (>/=65 years; >/=2 vomiting episodes, amnesia >30 minutes, pedestrian struc
177 f skull fracture, GCS score of 13, 2 or more vomiting episodes, decrease in GCS score, and pedestrian
178 ry recall of postingestive aversive effects (vomiting), evoked by repeatedly touching the food with c
179 than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal res
180       He did not have a history of nausea or vomiting, fever, weight loss, headache, photophobia, sei
181 fied acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced nee
182 2%] vs four [4%] postoperatively), nausea or vomiting (four [3%] vs six [4%] preoperatively; four [4%
183 were pulmonary embolism (four patients; 8%), vomiting (four; 8%), dehydration (three; 6%), and diarrh
184 rated gastric emptying (P < .03) and reduced vomiting frequency (by approximately 60%) and severity v
185 ite score of these 4 subjective symptoms and vomiting frequency and severity.
186  daily e-diaries, in which patients recorded vomiting frequency and symptom scores (nausea, abdominal
187 nts given relamorelin had a 75% reduction in vomiting frequency compared with baseline, but this diff
188       Hospitalization rates and diarrhea and vomiting frequency were not significantly different betw
189       Endpoints were change from baseline in vomiting frequency, composite DG Symptom Severity score,
190  reduction in gastroenteritis, diarrhea, and vomiting GP in-hours consultations in children aged 0-4
191 vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (
192  neratinib vs 23 [2%] grade 3 with placebo), vomiting (grade 3: 47 [3%] vs five [<1%]), and nausea (g
193 puncture for chemotherapy-induced nausea and vomiting had low ROB.
194 l intake of ferrous iron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and cons
195 .89; 95% confidence interval [CI], .82-.97), vomiting (HR, 0.86; 95% CI, .75-.98), and fever (HR, 0.9
196 linking food exposure to typical symptoms of vomiting, hypotension, and diarrhea has lagged far behin
197  (eight grade 1 and five grade 2), nausea or vomiting in 15 patients (38%) (ten grade 1 and five grad
198 rse events were gastrointestinal (nausea and vomiting in four participants during pregnancy and three
199 e outbreaks that causes diarrhoea, fever and vomiting in humans.
200 s) are leading causes of severe diarrhea and vomiting in infants and young children.
201 revention of chemotherapy-induced nausea and vomiting in paediatric patients being treated with moder
202 e prevention of acute and delayed nausea and vomiting in patients receiving chemotherapy.
203  olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemoth
204 revention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of
205 revention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of
206 d to prevent chemotherapy-induced nausea and vomiting in patients with cancer.
207 n and a 30% reduction in odds of posttussive vomiting in persons aged 19 months-64 years.
208  findings suggest an effective treatment for vomiting in positive FPIES OFCs and allow for more confi
209 dence on effective treatments for nausea and vomiting in pregnancy and hyperemesis gravidarum.
210 y end points were control of both nausea and vomiting in the acute posttreatment period (first 24 hou
211                                 Inclusion of vomiting in the case definition resulted in a 20% improv
212 , respectively), and incidence of nausea and vomiting in the PACU (4 of 19 [21.1%] and 6 of 24 [25%],
213  and 6 of 23 [26.1%] for incidence of nausea/vomiting in the PACU).
214  or less, parent-reported moderate or severe vomiting in the previous 24 h, parent-reported severe fe
215 rrhea (in 51%), abdominal pain (in 40%), and vomiting (in 34%).
216  participants), abdominal pain (in six), and vomiting (in five).
217 luded cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%]).
218              Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic
219  gain resulting from compensatory behaviors (vomiting, laxative use, fasting, overexercise) was signi
220 he multivariate logistic model, a history of vomiting, lower platelet count, elevated aspartate amino
221 12), weight loss (LR, 4.7; 95% CI, 2.1-7.2), vomiting (LR, 4.6; 95% CI, 2.5-8.0), and swollen lymph n
222 ing, urinary retention, increased nausea and vomiting, may delay same day discharge.
223 erature, age, recession, wheeze, asthma, and vomiting (mnemonic STARWAVe; AUROC 0.81, 0.76-0.85) dist
224                          Severe AEs included vomiting (n = 32), dizziness (n = 16), headache (n = 11)
225 were anaemia (n=14), weight loss (n=12), and vomiting (n=10).
226 ), cough (n=32), nasopharyngitis (n=25), and vomiting (n=25).
227                                              Vomiting, nausea, and headache were the only treatment-e
228                                              Vomiting, nausea, asthenia/fatigue, and anorexia were co
229 ntly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, wh
230  (ie, complete protection, total control, no vomiting, no nausea, score of Functional Living Index-Em
231 ho achieved complete response (defined as no vomiting, no retching, and no use of rescue medication)
232 ns: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic
233                                    Nausea or vomiting occurred more frequently in the sertraline vs p
234 henia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the m
235  Hyperemesis gravidarum or severe nausea and vomiting of pregnancy affects women's physical, social a
236 east moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 m
237                                              Vomiting of the study medication occurred significantly
238                    The primary end point was vomiting on POD 2.
239 oup (one had right loin pain, diarrhoea, and vomiting; one had malaise, headache, and chest pain; and
240                      There was no history of vomiting or altered bowel habits.
241 an 18 years, with at least three episodes of vomiting or diarrhoea in the preceding 24 h and fewer th
242 ion to hospital (32 were pneumonia, two were vomiting or feeding disorders, one was septicaemia, and
243 ), intense fatigue or weakness (n=495, 68%), vomiting or nausea (n=365, 50%), and diarrhoea (n=294, 4
244  to withhold opioids when ADEs (i.e., nausea/vomiting or oversedation) were present together with hig
245  point was rate of complete response (ie, no vomiting or rescue treatment) from days 2 to 5 after che
246 abdominal discomfort for two months; nausea, vomiting or weight loss were not reported.
247 toms (OR 3.4 (1.8-6.7) vs mild symptoms) and vomiting (OR 3.1 (1.5-6.3).
248 rpse, body fluids, or a case with diarrhoea, vomiting, or bleeding).
249 tool specimens in children with diarrhoea or vomiting, or both.
250 in eating disorder symptoms such as binging, vomiting, or laxative abuse were observed between the se
251 between treatment arms with postdose nausea, vomiting, or other adverse events.
252 ia (P = .0012), GERD (P = .0001), and nausea/vomiting (P < .0001).
253 hea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at admission.
254 king were presence of abdominal bloating and vomiting (p < 0.05).
255 y to have myalgias/arthralgias (P< .001) and vomiting (P = .02).
256 al functioning (P </= .001), less nausea and vomiting (P = .029 and .031, respectively) and less pain
257 ted less pain (p=0.0008) and less nausea and vomiting (p=0.02) and constipation (p=0.02).
258 eral nervous system, such as chronic nausea, vomiting, pain, and hypertension.
259 ale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning,
260 engue Identifier [ESDI]) included history of vomiting, platelet count, AST level.
261 ehydration (eight each [4%]), and diarrhoea, vomiting, pneumonia, and decreased appetite (four each [
262                     Postoperative nausea and vomiting (PONV) continues to be one of the most common p
263 hyroidectomy reduce postoperative nausea and vomiting (PONV) in a randomized controlled trial?
264 ncluding migraines, postoperative nausea and vomiting (PONV), vertigo and morning sickness and observ
265 se for treatment of postoperative nausea and vomiting (PONV).
266 sia use, multimodal postoperative nausea and vomiting prophylaxis, multimodal sedation-hypnosis, and
267                 Among patients with baseline vomiting, relamorelin had prokinetic effects and signifi
268 dications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and
269 er of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95
270           The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatm
271                                              Vomiting, retching, or need for rescue antiemetic treatm
272 py with high chemotherapy-induced nausea and vomiting risk (32.4% [n = 106795]).
273 health problems, such as acute gastritis and vomiting, road accident, high fever, or cardiovascular d
274 o, risk difference 3.7%, 95% CI 1.8-6.1) and vomiting (RR 2.43, 95% CI 1.83-3.23; p<0.0001; 8.0% osel
275 cores over the 14-day study period, trend in vomiting scores was better in the ondansetron group (P =
276 patient questionnaires showed a reduction in vomiting (severity), diarrhea (both incidence and severi
277  history of lower abdominal pain, nausea and vomiting since 2 days which was gradual in onset and pro
278 VD case included hiccups, anorexia, fatigue, vomiting, sore throat, and difficulty swallowing.
279  hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psycholo
280                         Children with cyclic vomiting syndrome (CVS) have a high degree of maternal i
281 p), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [2%] patients in each group); and nervous
282 (four [11%]), hypertension (four [11%]), and vomiting (three [8%]).
283    In the 119 patients (58.3%) with baseline vomiting, twice-daily relamorelin significantly reduced
284 cal neurologic deficits, chest pain, nausea, vomiting, unintentional weight loss, or recent trauma.
285 usion, conjunctivitis, hiccups, diarrhea, or vomiting was associated with increased likelihood of con
286                  An important improvement of vomiting was observed in all three treatment groups.
287                            The occurrence of vomiting was significantly higher in rotavirus diarrhea
288                                              Vomiting was the most commonly reported mild adverse eve
289 based on the percentage of cases who stopped vomiting, was compared in cases who received parenteral
290                       Women reporting nausea/vomiting were less likely to be adherent in both the tam
291                      Diarrhoea and nausea or vomiting were more common in the metformin group than in
292                        Burping and nausea or vomiting were most severe in patients with cachexia (p <
293 nt), and headache, dizziness, diarrhoea, and vomiting were the most frequent adverse events in patien
294 testinal side effects (nausea, loose stools, vomiting) were common but did not limit therapy.
295 , retinal vein occlusion, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each).
296 nic trioxide because of grade 3 diarrhea and vomiting with concurrent grade 3 hypokalemia and hyponat
297  spp, fever and vomiting with rotavirus, and vomiting with norovirus GII.
298 ampylobacter spp and Shigella spp, fever and vomiting with rotavirus, and vomiting with norovirus GII
299                                              Vomiting without diarrhea occurred among norovirus cases
300       Safety outcomes were the prevalence of vomiting, witnessed aspiration, and ICU-acquired pneumon

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top